glp-1 receptor agonists muscle mass preservation 2025 Balancing weight and loss in GLP1 agonist therapy Strategies to prevent loss of

Insurers generally seek to avoid changes in risk that they don't understand

Some orthopedic surgeons may perceive the growing use of GLP-1 receptor agonists as a potential threat to their practice, fearing that widespread weight loss could reduce the volume of patients requiring joint replacements

"But there isn't enough evidence to know whether these drugs might be beneficial or dangerous for people who fall outside of the FDA criteria," says Dr

I got a letter of rejection stating that my Geisinger Gold would not cover it

Ipragliflozin, one of the SGLT2 inhibitors, was the first such agent to obtain regulatory approval in Japan on January 17, 2014

doi: 10.1016/j.regpep.2004.08.026